Sign up for free to view insider transactions by individual.
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Why Is Syndax Pharmaceuticals (SNDX) Drawing So Much ASH 2026 Attention?
Syndax Pharmaceuticals Inc (SNDX) (Q3 2026) Earnings Call Highlights: Revenue Surges 82% as ...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026
Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is The Key
Syndax Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
Syndax Pharmaceuticals Stock Gains Focus After Revenue Growth And Pipeline Progress
Syndax Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Syndax Pharmaceuticals (SNDX) Stock May Be Rich After Revuforj Award Win
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $36
Syndax Pharmaceuticals (SNDX) Missed On Q3 Results, Is The 65% Undervaluation Case Still Intact?
Syndax (SNDX) Q3 2026 Earnings Call Transcript
Syndax: Q3 Earnings Snapshot
What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2026 Earnings Call Transcript
Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.